RxDoctor Payments Data

Jonathan Wheeler, MD

Family Medicine · Saint Helena, CANPI 1013919752

Payments from drug & device makers

$2,560in general payments, 2019–2025

Across 102 payments — averaging $25.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$343
  • Boehringer Ingelheim$342
  • Novo Nordisk$284
  • AbbVie$231
  • Abbott$183
  • Teva Pharmaceuticals USA, Inc.$175
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,551100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,560 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$178,958
Medicare patients
406
Services billed
3,725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin101$114,364
OzempicSemaglutide48$61,565
EliquisApixaban55$33,994
TrulicityDulaglutide18$23,220
MyrbetriqMirabegron16$11,100
SymbicortBudesonide/Formoterol Fumarate31$6,838
Nebivolol Hcl12$2,555
Rosuvastatin Calcium156$2,199
Levothyroxine Sodium203$1,773
Sertraline Hcl23$1,717
PaxlovidNirmatrelvir/Ritonavir14$1,429
Atorvastatin Calcium188$1,405
Tamsulosin Hcl83$1,208
Amlodipine Besylate177$1,080
Albuterol Sulfate HfaAlbuterol Sulfate35$1,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$342$114,364101 claims
Novo NordiskOzempic$284$61,56548 claims
PfizerEliquis, Paxlovid$32$35,42369 claims
Lilly USA, LLCTrulicity$156$23,22018 claims
AstraZenecaSymbicort$151$6,83831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Saint Helena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →